We Offer Worldwide Shipping
Login Wishlist

Soyasapogenol C

$560

  • Brand : BIOFRON

  • Catalogue Number : BD-P0445

  • Specification : 98.0%(HPLC)

  • CAS number : 595-14-2

  • Formula : C30H48O2

  • Molecular Weight : 440.701

  • Volume : 5mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BD-P0445

Analysis Method

HPLC,NMR,MS

Specification

98.0%(HPLC)

Storage

2-8°C

Molecular Weight

440.701

Appearance

Powder

Botanical Source

Structure Type

Triterpenoids

Category

SMILES

CC1(CC2C3=CCC4C5(CCC(C(C5CCC4(C3(CCC2(C=C1)C)C)C)(C)CO)O)C)C

Synonyms

(3~{S},4~{S},4~{a}~{R},6~{a}~{R},6~{b}~{S},8~{a}~{S},12~{a}~{R},14~{a}~{R},14~{b}~{R})-4-(hydroxymethyl)-4,6~{a},6~{b},8~{a},11,11,14~{b}-heptamethyl-1,2,3,4~{a},5,6,7,8,12,12~{a},14,14~{a}-dodecahydropicen-3-ol

IUPAC Name

Applications

Density

Solubility

Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.

Flash Point

Boiling Point

Melting Point

InChl

InChI=1S/C30H48O2/c1-25(2)14-15-26(3)16-17-29(6)20(21(26)18-25)8-9-23-27(4)12-11-24(32)28(5,19-31)22(27)10-13-30(23,29)7/h8,14-15,21-24,31-32H,9-13,16-19H2,1-7H3/t21-,22+,23+,24-,26+,27-,28+,29+,30+/m0/s1

InChl Key

VNGUCOGHCJHFID-FLZFTVBESA-N

WGK Germany

RID/ADR

HS Code Reference

2933990000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:595-14-2) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

27374104

Abstract

Down’s syndrome occurs when a person has three, rather than two copies of chromosome 21; or the specific area of chromosome 21 implicated in causing Down’s syndrome. It is the commonest congenital cause of mental disability and also leads to numerous metabolic and structural problems. It can be life‐threatening, or lead to considerable ill health, although some individuals have only mild problems and can lead relatively normal lives. Having a baby with Down’s syndrome is likely to have a significant impact on family life.

KEYWORDS

myelodysplasia, ribosome, microRNA, haemopoiesis, chromosome

Title

RPL27A is a target of miR-595 and may contribute to the myelodysplastic phenotype through ribosomal dysgenesis

Author

Heba A. Alkhatabi,1,2 Donal P. McLornan,1,3 Austin G. Kulasekararaj,1,3 Farooq Malik,1 Thomas Seidl,1 David Darling,1 Joop Gaken,1,* and Ghulam J. Mufti1,3,*

Publish date

2016 Jul 26;

PMID

29042803

Abstract

Background
Chronic hepatitis C remains a major global health burden with serious long-term consequences if left untreated. Recently the treatment standard of care has shifted to new interferon (IFN)-free drug regimens, which have been shown to be safe and effective. The aim of our study was to assess and compare medical resource utilization and costs of successfully treating patients with IFN-based and IFN-free therapies in Australia.

Methods
We performed a retrospective chart review of 30 HCV-infected patients successfully treated with IFN-based therapy between 2013 and 2015. We also generated a model for a virtual group of 100 genotype 1 (GT1) and 100 genotype 3 (GT3) patients treated with IFN-free therapy derived from national guidelines and clinical trial data.

Results
In comparison to virtual patients receiving IFN-free therapy, our IFN-treated patients on average had distinctively more liver clinic visits and blood tests. However, mean total cost per patient was $19,164 and $85,300 (AUD) more for GT1 and GT3 patients receiving IFN-free therapy, respectively. This difference was largely accounted for by higher antiviral drug costs. Of our 30 patients treated with IFN, total mean cost per patient during the study period was $33,595.

Conclusion
Resource utilization is lower with IFN-free treatment, which reflects the reduced need for patient monitoring and improved side-effect profile of these new drugs. However, total costs are still largely dominated by antiviral drug costs, representing a huge burden on national budgets. Our insight into resource utilization and costs associated with both types of treatment can serve as a reference for future studies.

KEYWORDS

antiviral treatment, chronic hepatitis C, comparison, costs, real-life setting, resource utilization

Title

The cost of successful antiviral therapy in hepatitis C patients: a comparison of IFN-free versus IFN-based regimens at an individual patient level in Australia

Author

Allister Sebastian Lee,1 Mieke L van Driel,2 and Darrell HG Crawford3,4

Publish date

2017;

PMID

4286884

Abstract

davie, joseph M. (Indiana University, Bloomington), and thomas d. brock. Action of streptolysin S, the group D hemolysin, and phospholipase C on whole cells and spheroplasts. J. Bacteriol. 91:595-600. 1966.—The effect of streptolysin S, the group D hemolysin, and phospholipase C (the α toxin of Clostridium perfringens) on whole cells and spheroplasts or protoplasts of three strains of streptococci and Micrococcus lysodeikticus was tested. Viability, C14-glycine uptake, and lysis were measured. The group D hemolysin and phospholipase C were active against whole bacteria; streptolysin S was not. All three substances were active on spheroplasts. A partially resistant mutant derived from a strain sensitive to the group D hemolysin was also partially resistant to streptolysin S and phospholipase C. Antimycin A protected spheroplasts from streptolysin S but not from the group D hemolysin.

Title

Action of Streptolysin S, the Group D Hemolysin, and Phospholipase C on Whole Cells and Spheroplasts

Author

Joseph M. Davie1 and Thomas D. Brock2

Publish date

1966 Feb